The Provenge Precedent

Dendreon's therapeutic cancer vaccine Provenge is the first of its kind to make it to an FDA advisory committee. The committee gave the novel agent a thumbs up. But FDA may disagree and turn away the prostate cancer vaccine until there is more conclusive data of its safety and effectiveness. How much does Dendreon stand to lose?

By Ramsey Baghdadi

In an industry where all drug approvals and rejections are put under the microscope, Dendreon Corp. ’s therapeutic cancer vaccine...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Platform Technologies

More from Advanced Technologies